Abstracts tagged "cutaneous lupus erythematosus and interferons"

Abstract Number: 2933 • 2018 ACR/ARHP Annual Meeting
Non-Invasive Tape Sampling Reveals RNA Gene Clusters in Cutaneous Lupus Erythematosus That Discriminate Affected from Unaffected and Healthy Volunteer Skin
Joseph F. Merola¹, Wenting Wang², Carrie Wager³, Stefan Hamann², Xueli Zhang³, Alice Thai², Chris Roberts², Christina Lam⁴, Cristina Musselli², Galina Marsh², Dania Rabah², Catherine Barbey⁵, Nathalie Franchimont² and Taylor L. Reynolds², ¹Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Biogen, Cambridge, MA, ³Formerly of Biogen, Cambridge, MA, ⁴Boston University Medical School, Boston, MA, ⁵Biogen, Zug, Switzerland
Background/Purpose: Punch biopsy, the standard diagnostic and monitoring procedure for patients with cutaneous lupus erythematosus (CLE), impedes patient recruitment and follow up due to risk…
Abstract Number: 2857 • 2016 ACR/ARHP Annual Meeting
Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
Jessica Schreiter¹, Jarrat Jordan¹, Matteo Cesaroni¹, Marc Chevrier², Alexa Piantone³, Ian Gourley³, Jacqueline Benson¹ and Takahiro Sato¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, LLC, Collegeville, PA, ³Immunology Translational Medicine, Janssen Pharmaceutical Research and Development, LLC, Spring House, PA
Background/Purpose: Type I IFN (IFN-I)-regulated gene expression is known to be elevated in blood and skin lesions of patients with two different forms of cutaneous…
Abstract Number: 3240 • 2016 ACR/ARHP Annual Meeting
Interferon Kappa Is a Novel Type I IFN That Drives Cutaneous Inflammation in Systemic Lupus
Jasmine Stannard¹, Tamra J. Reed², Emily Myers³, Lori Lowe⁴, Mrinal Sarkar⁴, Xianying Xing⁵, Celine C. Berthier⁶, Johann Gudjonsson⁴ and J. Michelle Kahlenberg⁷, ¹Int. Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Rheumatology, Georgetown University, Washington, DC, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Dermatology, University of Michigan, University of Michigan, Ann Arbor, MI, ⁶Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁷Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are disfiguring, scarring, difficult to treat, and affect up to 70% of patients with systemic lupus erythematosus (SLE). Type…